Cancer Target Agents 02-10-16

123456789101112131415161718192021222324
Across
  1. 3. MOA-delivers diphtheria toxin and IL2 to cells expressing IL2 receptor (CD 25)
  2. 4. Binds to BCR-ABL to prevent unregulated cell growth/proliferation
  3. 6. Indicated for Relapsed/refractory T-Cell Lymphoma, Side effects include QT prolongation and SJS rash
  4. 8. CBC weekly for first month then biweekly for the second month
  5. 10. Is an VEGF inhibitor that blocks angiogenesis and should be held for 28 days prior to surgery and restarted 28 days later.
  6. 13. VEGF Inhibitor that Inhibits angiogenesis and can lead to hemorrhage
  7. 16. blocks activity at the 26S proteasome, leading to inhibition of cell growth
  8. 19. Inhibits EGFR and HER2 tyrosine kinase, ultimately leading to cell death
  9. 20. mTor inhibitor that should be used in caution with bilirubin > 1.5x ULN
  10. 22. this ia a Poly ADP-ribose polymerase inhibitor (PARP)
  11. 23. Side effects include rhabdo
Down
  1. 1. MOA-HSV-1 virus that lyses tumor cells
  2. 2. Side effects include taste changes, QT prolongation and pulmonary embolism.
  3. 5. moa-is a CDK 4 and 6 inhibitor
  4. 7. Side effects include the reactivation of Hep B and tumor lysis syndrome which can lead to renal failure.
  5. 9. Monitor for LVEF at baseline or every 3 months, s/sx of pulmonary/cardio toxicity
  6. 11. monitor serum electrolytes periodically, and pregnancy test 1 week prior to tx
  7. 12. irreversible inhibitor of 20S proteasome, Side effects include acute liver failure.
  8. 14. Indicated for NSCLC and pancreatic cancer, PPI’s and H2s can decrease absorption
  9. 15. indicated for Multiple Myeloma after 2 failed tx’s
  10. 17. Side effects include T2DM new onset, hypercholesterolemia, TG ↑
  11. 18. Monitor serum Mg++, K+, and Ca++ levels every 8 weeks
  12. 21. Inhibits delta Phosphatidylinositol 3-kinase (PI3K-delta)
  13. 24. reversibly inhibits beta 5 subunit of 20S proteasome, side effects include blurred vision, thrombocytopenia, neutropenia, and conjunctivitis.